Actavis, a global pharmaceutical company, launched its new Asian-Pacific and Africa headquarters in Singapore on Thursday.

The company, which has been present in the Singapore healthcare market through subsidiary, Drug Houses of Australia (DHA), produces tablets, capsules, oral solutions, dry suspensions, ointments and liniments.

Actavis chairman and chief executive officer Paul Bisaro also announced that DHA will come under the Actavis brand.

"By centralising our regional operations in Singapore, we will be better positioned to focus on strategies that will strengthen our growth in emerging markets across Southeast Asia, enabling consumers to have increased access to affordable, high-quality medicines that help them live longer, healthier lives," he said in a statement.

The company, which has 130 employees in Singapore, hopes to double its revenue in Southeast Asia within the next five years.

Actavis currently derives US$250 million in revenue from the region.